Granules India Limited

Overview

Granules India Limited is a prominent Indian multinational pharmaceutical company based in Hyderabad, Telangana. Established in 1984, it specializes in the development, production, and distribution of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). With a strong presence in over 80 countries, including regulated markets like the US and Canada, the company has built a reputation for quality and operational excellence.

The organization operates 10 manufacturing facilities, primarily in India, and has a notable joint venture in Wuhan, China. Its Gagillapur plant is recognized for being the world's largest PFI facility. Granules India invests significantly in research and development, focusing on cost-effective manufacturing processes and innovative drug delivery systems. Its product portfolio includes widely used off-patent drugs such as Paracetamol, Ibuprofen, and Metformin, catering to a diverse customer base of leading pharmaceutical companies globally.

Basic Information

Contact Details

• Website: granulesindia.com
• LinkedIn: linkedin.com/company/granules-india-limited

Key Focus Areas & Initiatives

• Large scale pharmaceutical manufacturing
• Pharmaceutical manufacturing
• Regulatory approvals
• High-volume production
• API production
• Customer centricity
• Regulatory pathway optimization
• Product lifecycle management
• Regulatory submission support
• R&D innovation
• API manufacturing
• Product commercialization
• Quality control
• Supply chain management
• Advanced manufacturing techniques
• Contract research organization
• Regulatory strategy for US market
• Regulatory compliance
• Cost reduction
• Specialty API manufacturing
• Regulatory support
• Market penetration
• Regulatory approvals process
• Manufacturing technology
• Quality manufacturing
• Sustainability
• Regulatory risk management
• Innovation
• Healthcare
• Regulatory documentation excellence
• Contract manufacturing
• Process optimization
• Pharmaceuticals
• Regulatory affairs
• Specialty pharma
• Regulatory filings
• Global presence
• Manufacturing excellence
• Finished dosages
• Product pipeline
• Product development
• Research and development
• Market-specific regulatory strategy
• Sustainable process development
• Biotechnology
• High potency products
• Quality management
• Regulatory submissions
• Specialty products
• Innovative drug delivery
• Market access
• Multi-site facilities
• Regulatory approval timelines
• Global supply chain
• Specialty formulations
• India-based pharma
• Process innovation
• Clinical trial support
• Regulatory intelligence
• Regulatory environment
• Advanced process development
• Regulatory filing strategy
• Regulatory dossier management
• Regulatory strategy
• Regulatory compliance consulting
• Product portfolio
• USFDA
• Customized formulations
• Cost efficiency
• Globally integrated
• Sustainable manufacturing
• Green chemistry processes
• Custom synthesis
• Biosimilar development
• Technology adoption
• Regulatory audits
• Quality standards
• API development
• API process innovation
• Oncology products
• Product registration
• Manufacturing scale-up
• Biotech collaborations
• Market expansion
• Cost-effective medicines
• Pharmaceutical and medicine manufacturing
• Market-specific formulations
• Sustainable growth
• Regulatory approval support
• Formulation intermediates
• B2B
• Product innovation
• Oncology APIs
• Biosimilars
• Quality assurance
• Regulatory documentation
• Finance
• Manufacturing
• Distribution
• Transportation & logistics
• Medical
• Logistics & supply chain
• Environmental services
• Renewables & environment
• Health care
• Health, wellness & fitness
• Hospital & health care
• Mechanical or industrial engineering
• Research & development
• Financial services

Technologies Used

• Outlook
• Remote

Affiliated Organizations & Regional Branches

• Senn Chemicals AG
• AUCTUS PHARMA LIMITED